Quarterly ResultApr 28, 2026, 05:02 PM
NEO Q1 Revenue +11% to $187M; Raises FY26 Revenue Guidance
AI Summary
NeoGenomics, Inc. reported strong first quarter 2026 results, with total revenue increasing 11% year-over-year to $187 million, driven by a 14% rise in clinical revenue. The company significantly reduced its net loss by 34% to $17 million and achieved positive Adjusted EBITDA of $9 million, a 27% increase. Operational highlights include the launch of RaDaR® ST MRD assay and PanTracer Pro, alongside favorable MolDX coverage for PanTracer™ LBx. Consequently, NeoGenomics raised its full-year 2026 revenue guidance to a range of $797-$803 million.
Key Highlights
- NEO Q1 2026 total revenue increased 11% YoY to $187 million.
- Clinical revenue grew 14%, with NGS growth of 26%.
- Net loss decreased 34% to $17 million.
- Adjusted EBITDA was positive $9 million, up 27% YoY.
- Launched RaDaR® ST ctDNA assay for molecular residual disease (MRD).
- Announced favorable MolDX coverage for PanTracer™ LBx.
- Introduced PanTracer Pro for advanced-stage solid tumors.
- Increased full-year 2026 revenue guidance to $797-$803 million.